Mannkind (MNKD) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.24% |
| Dec 31, 2025 | -41.31% |
| Sep 30, 2025 | 53.43% |
| Jun 30, 2025 | -16.82% |
| Mar 31, 2025 | -35.83% |
| Dec 31, 2024 | -126.83% |
| Sep 30, 2024 | -31.90% |
| Jun 30, 2024 | -34.52% |
| Mar 31, 2024 | -4.30% |
| Dec 31, 2023 | 20.69% |
| Sep 30, 2023 | 27.43% |
| Jun 30, 2023 | 21.03% |
| Mar 31, 2023 | 22.53% |
| Dec 31, 2022 | -11.37% |
| Sep 30, 2022 | 22.93% |
| Jun 30, 2022 | -47.19% |
| Mar 31, 2022 | -33.69% |
| Dec 31, 2021 | 50.55% |
| Sep 30, 2021 | 17.49% |
| Jun 30, 2021 | -48.17% |
| Mar 31, 2021 | 50.63% |
| Dec 31, 2020 | -11.18% |
| Sep 30, 2020 | 31.97% |
| Jun 30, 2020 | 30.49% |
| Mar 31, 2020 | 395.51% |
| Dec 31, 2019 | 65.11% |
| Sep 30, 2019 | -33.39% |
| Jun 30, 2019 | -43.06% |
| Mar 31, 2019 | -0.90% |
| Dec 31, 2018 | 35.92% |
| Sep 30, 2018 | -17.52% |
| Jun 30, 2018 | -24.64% |
| Mar 31, 2018 | 8.99% |
| Dec 31, 2017 | -14.00% |
| Sep 30, 2017 | 4.86% |
| Jun 30, 2017 | 28.58% |
| Mar 31, 2017 | -14.11% |
| Dec 31, 2016 | 8.87% |
| Sep 30, 2016 | -70.04% |
| Jun 30, 2016 | 29.41% |
| Mar 31, 2016 | -10.41% |
| Dec 31, 2015 | 23.05% |
| Sep 30, 2015 | -25.13% |